Behavioural studies have yielded results that show lobeline has the ability to attenuate d-methamphetamine self-administration. Further in vivo and in vitro studies have demonstrated a blockade of μ-opioid receptors with lobeline. The present investigation examined the ability of lobeline to attenuate heroin intravenous (i.v.) self-administration when administered prior to testing. Male Sprague-Dawley rats were surgically implanted with jugular catheters and trained to lever press for i.v. heroin infusions (18 μg/kg) under a fixed ratio-2 schedule wherein two active lever presses resulted in heroin delivery. Rats then were tested for heroin self-administration after pretreatment with subcutaneous lobeline injections (0.3, 1.0, or 3.0 mg/kg, 15 min prior to testing sessions). At doses of 1.0 and 3.0 mg/kg, lobeline attenuated self-administration of heroin. The results suggest a potential for lobeline to be used in pharmacotherapy for opioid abuse.
Lobeline (LOB) is the most biologically active alkaloidal component synthesized from Indian Tobacco (Lobelia inflata). In addition to its high affinity for α 4 β 2 subtypes of the nicotinic acetylcholine receptor, LOB is also believed to alter dopaminergic neurotransmission by interrupting the activity of vesicular monoamine transporter-2s (VMAT2) (Felpin and Lebreton, 2004) , theoretically inhibiting vesicular dopamine (DA) transport within the pre-synaptic terminal.
Recent studies have focussed on the ability of LOB to alter behavioural effects of drugs of abuse, particularly psychostimulants. Pretreatment with a low dose of LOB that would cause no behavioural effect on its own has been shown to attenuate d-methamphetamine-induced hyperactivity in mice (Miller, et al., 2001) . A dose-dependent effect of LOB on the development of sensitization to cocaine-induced hyperactivity also has been demonstrated (Polston, et al., 2006) . Specifically, at a dose of 0.3 mg/kg LOB was found to augment cocaineinduced hyperactivity brought about by repeated administration of 10-20 mg/kg cocaine in rats, but at the 1.0 mg/kg dose of LOB the development of cocaine-induced hyperactivity with repeated administration was prevented. Neither dose was effective when the cocaine dose was 30 mg/kg. Elsewhere, pretreatment with LOB at doses ranging from 3.0 to 30 mg/kg, 15 min prior to administration of d-methamphetamine has been shown to decrease the intensity of stereotype in imprinting control region mice (Tatsuta, et al., 2006) . In a study that examined whether LOB would be self-administered by rats, it was demonstrated that rats would not self-administer for LOB either alone, or in place of d-methamphetamine (Harrod, et al., 2003) . Based on evidence from in vitro studies that demonstrated the ability of LOB to interrupt d-methamphetamine dopaminergic neurotransmission, Harrod, et al. (2001) conducted a d-methamphetamine self-administration study that revealed how pretreatments with LOB (0.3-3.0 mg/kg, 15 min prior to testing) attenuated lever pressing for intravenous (i.v.) d-methamphetamine in rats, thus demonstrating the potential use of LOB in pharmacotherapy for methamphetamine addiction. DA release is a common factor with numerous drugs of abuse (Wise and Bozarth, 1987) , and is thought to be responsible for the 'wanting' of a drug that develops with repeated administrations (Berridge, 2007; Salamone, et al., 2007) . Consequently, the ability of LOB to interrupt dopaminergic neurotransmission may implicate a practical application in treatment for drug addiction that extends beyond psychostimulants.
A recent study found that LOB has a high affinity for opioid receptors. That is, LOB pretreatment attenuates opiate-induced hyperactivity, and it prevents the development of sensitization to morphine (Miller, et al., 2007) . As noted, LOB has been shown to bind to and inhibit VMAT2s (Eyerman and Yamamoto, 2005; Teng, et al., 1998) . This inhibition of vesicular DA transport within the pre-synaptic terminal may affect opiate sensitivity, similar to the manner in which it affects psychostimulant sensitivity, as demonstrated by the reduced psychostimulant-conditioned reward seen in VMAT2 knock-out mice (Takahashi, et al., 1997) . At this juncture the effects of LOB on i.v. opiate self-administration are not known.
Heroin, once it reaches the brain, is converted to morphine, which then binds to μ-opiate receptors acutely expressed on ventral tegmental area (VTA) interneurons and on nucleus accumbens (NAc) neurons (Hyman, et al., 2006) . These inhibitory gamma-Aminobutyric acid (GABA) neurons in the region of the VTA modulate tonic glutamate (Glu) activation of dopamine neurons projecting to the NAc, therein producing rewarding effects. In this cascade, when opiates bind to the µ receptors on GABA fibres they operate as antagonists. The resulting disinhibition of Glu stimulation permits elevated levels of DA to accrue in the NAc, thereby defining the rewarding properties of heroin. It is possible that LOB may competitively or noncompetitively antagonize opiate action at the µ-receptor site (cf. Miller, et al., 2007) , thus interfering with the disinhibitory effects of heroin that would otherwise occur. Certainly, the ability of LOB to inhibit opiate-induced DA release in a manner similar to its inhibition of d-methamphetamine-induced DA release necessitates an examination of its ability to attenuate heroin self-administration, in as much as DA is involved in defining the rewarding properties of heroin (Bozarth and Wise, 1981; White and Kalivas, 1998; Koob and Le Moal, 2001; Le Foll, et al., 2005) . Accordingly, the purpose of the present investigation was to test the hypothesis that pretreatment with LOB would attenuate heroin self-administration in rats. In this investigation, animals shaped to self-administer heroin were pretreated with LOB administered subcutaneously (s.c.) and subsequently tested for differential heroin self-administration.
Materials and methods

Animals
Seven adult male Sprague-Dawley rats (Harlan; Houston, TX USA) approximately 60 days old at the time of their arrival at the laboratory were used in this study. Body weights ranged from 250 to 300 g. All animals were individually housed in standard hanging plastic cages in a temperature and humidity controlled room with a 12/12-h light/dark cycle. Animals had continuous access to standard rat chow (Teklad, Madison, Wisconsin, USA) and tap water throughout the experiment.
Surgical procedures
Details of the surgical procedures have been presented earlier (Rocha, et al., 2008; Valles, et al., 2005) . Briefly, after allowing the animals to acclimate to the vivarium for 7 days, chronic indwelling jugular catheters were implanted in rats. Rats were anaesthetized with separate injections of 60 mg/kg ketamine and 20 mg/kg sodium pentobarbital. A catheter consisting of 0.25-mm interior diameter (ID)/0.76-mm outside diameter (OD) Silastic tubing (Dow Corning; Midland, Michigan, USA) was inserted into the right jugular vein and sutured to muscle tissue in the area of the vein. Using an 11-ga stainless steel tube as a guide, the catheter was passed s.c. through the body of the animal and exited the back between the scapulae. A backplate consisting of two stainless steel ovals separated by polypropylene mesh (Ethicon, Inc.; Sommerville, New Jersey, USA) accommodated a spring leash, through which the catheter was threaded. Connecting to the backplate at one end, the other end of the leash was connected to a single fluid channel swivel. Swivels were made in-house using 20-ga hypodermic tubing, a 20-ga needle, a 1-cc syringe, a 3-cc syringe and a rubber stopper. The swivel design permitted an interlock with separate connecting arms located in the home cage and operant conditioning chambers (see below). The movable arm allowed for free movement and delivery of appropriate solutions in either the home cage or test chamber. A 0.51-mm ID/1.53-mm OD catheter continued from the top of the swivel to an infusion pump that controlled solution delivery. The rats were allowed 5 days to recover from surgery before commencing self-administration testing. During this recovery period, each rat received in the home cage automated hourly i.v. infusions (8 s; .25 ml) of a sterile saline solution containing heparin (1.25 IU/ml). On self-administration test days, the cannulae were flushed with this solution daily following the test, and this solution was cleared with a subsequent application of 0.10 ml heparinized saline. Catheter patency was verified throughout the experiment by administering an i.v. infusion of 7.50 mg/kg sodium pentobarbital and checking for rapid onset of brief anaesthesia.
Apparatus
Seven operant conditioning chambers (Model E10-10; Coulbourn, Allentown, Pennsylvania, USA) in sound attenuating cubicles served as the test apparatus. Each chamber had two levers (left/inactive, right/active) and a stimulus light located above each lever. Infusion pumps (Razel Scientific Instruments; Stamford, Connecticut, USA) controlled drug delivery to each of the boxes. A 20-m1 syringe delivered 0.16 ml i.v. infusions over a 6-s time frame. The system was interfaced with an IBM computer controlling drug delivery and recording data from the seven chambers. Testing occurred during the light phase of the cycle.
Testing procedures
Baseline training commenced 5 days after catheter surgeries. Rats initially were shaped to lever press for a 6-s infusion of 0.50 mg/kg cocaine HCl on a fixed ratio (FR-1), where a single depression of the active (right) lever resulted in drug delivery and illumination of the stimulus light above the lever. After five consistent days of cocaine self-administration (>25 presses in a 2-h session), rats were shaped to lever press for an infusion of 18 μg/kg heroin under an FR-2 schedule, where two depressions of the active (right) lever were required for drug delivery. The use of the FR-2 schedule limits incidental drug delivery and thus provides a more accurate index of deliberate drug self-administration responding. After five consistent days of heroin self-administration (>25 presses in a 2-h session), rats received 5 days of s.c. saline injections 15 min prior to being placed in testing chambers for a 2-h session of heroin selfadministration. These last 5 days of saline injections were carried out to prevent animals from associating the s.c. injections with a reduced drug effect for heroin.
Dose-effect testing began the day immediately following the final day of baseline training. Rats were tested daily (1 day at each dose) for 1 h with escalating pretreatment doses of LOB (0.3, 1.0 and 3.0 mg/kg) administered s.c. 15 min prior to heroin self-administration testing sessions, with 2 days of saline only (SAL) pretreatment injections administered s.c. 15 min prior to 2-h heroin self-administration sessions (baseline) between escalating doses of LOB. The decision to employ an ascending drug regimen was based on a desire to limit carryover effects that sometimes occur with higher drug doses, i.e. feedforward (Pavlovian) conditioned cues from earlier testing sessions involving high drug doses may transfer to later test sessions and therein bias the results.
Drugs
The Research Technology Branch of the National Institute of Drug Abuse generously supplied the 3,6 diacetylmorphine HCl (heroin), and the drug was administered as the salt. Lobeline sulphate was purchased from Fisher Scientific (Pittsburgh, Pennsylvania, USA) and the drug was administered as the base.
Results
Behavioural data
With respect to the initial acquisition of the self-administration response a within-subjects Levers × Test Days Analysis of Variance (ANOVA) test performed on the last 5 days of acquisition training prior to commencing lobeline testing revealed a significant main effect for Levers [F(1,6) = 49.48, P < 0.01], but a nonsignificant main effect for Test Days was found [F(4,24) = 0.98, P > 0.05]. Tukey's post hoc tests showed the effect of Levers was due to greater responding on the right (active) lever than the inactive lever (P < 0.01). Subsequent comparisons of the five terminal acquisition test days indicated that test animals had reached asymptote with regard to active lever responding (means on successive test days were 37. 71, 44.85, 42.42, 37.71 and 40.71 ; P > 0.05).
Data for the mean number of right (active) lever presses for heroin infusions across lobeline test days are presented in Figure 1 along with the inactive (left lever) data. LOB doses of 1.0 and 3.0 mg/kg suppressed right lever pressing, but the 0.3 mg/kg dose did not. Statistical confirmation of differences was accomplished with a Levers (inactive, active) × Test Days (1-9) completely within subjects repeated measures ANOVA test. The analysis showed a main effect for the within group factor of Levers [F(1,6) = 55.11, P < 0.01], as well as a main effect for Test Days [F(8,48) = 12.67, P < 0.01]. In addition, a significant interaction for Levers × Test Days was also found [F(8,48) = 12.56, P < 0.01].
Tukey's post hoc tests revealed statistically significant contrasts for active vs. inactive lever pressing, with active lever responding exhibited at substantially higher rates (P < 0.01). Indeed, very few responses were committed to the inactive lever on any test day. With respect to individual comparisons of the relevant baseline and LOB dose testing days, the dose of 0.3 mg/kg LOB administration did not significantly alter active lever responding relative to the prior baseline levels (saline days 1 and 2). However, at LOB doses of 1.0 and 3.0 mg/kg heroin self-administration was significantly attenuated relative to the respective baseline days administered prior to LOB testing (Ps < 0.01). Finally, contrasts for the means for active lever pressing at the three LOB doses indicated that heroin selfadministration was lower at both the 1.0 mg/kg LOB dose and the 3.0 mg/kg LOB dose relative to a LOB dose of 0.3 mg/kg (P < 0.01), but with no statistically significant difference found when contrasting the LOB dose of 1.0 mg/kg against the LOB dose of 3.0 mg/kg (P > 0.05). Figure 1 Mean active (heroin) and inactive lever press rates per session and standard error values for dose-effect testing days (0.3, 1.0, 3.0 mg/kg LOB), and for the 2 days of baseline heroin self-administrations sessions preceding each dose.
Discussion
The present study tested the hypothesis that pretreatment with LOB would attenuate heroin self-administration in rats. The findings from this investigation demonstrated that LOB pretreatment effectively attenuates opiate self-administration in a dose-dependent manner. The lowest dose of LOB (0.3 mg/kg) had no effect, while attenuation of heroin self-administration was evident with LOB doses of 1.0 and 3.0 mg/kg. Our findings are in agreement with the findings of Miller, et al. (2007) where LOB was found to be a μ-opioid receptor antagonist, due to having a high affinity for μ-opioid receptors, thereby producing an inhibitory effect on opiate pharmacology.
It must be considered that the diminished active lever press rates exhibited under conditions of 1.0 and 3.0 mg/kg LOB may derive from compromises in the ability of animals to execute the requisite motor responses (lever presses). Along these lines, it has been noted in previous research that acute injections of LOB decreases locomotor activity in experimentally naïve rats (Stolerman, et al., 1995) . However, in the previous investigation suppression of motor activity occurred only at very high doses of LOB (e.g. 10 mg/kg), and at the doses used in the current experiment (0.3, 1.0 and 3.0 mg/kg body weight), no significant suppressive effects on motor activity were apparent. Accordingly, it is unlikely that the substantially reduced heroin self-administration response rates observed here when 1.0 and 3.0 mg/kg LOB pretreatments were administered were due solely to motor confounds.
A notable occurrence found in the data from the dose effect testing was the level of active (heroin) lever pressing on the subsequent baseline days (Figure 1 ). After the ineffective dose of LOB (0.3 mg/kg), lever presses for heroin infusions on the following baseline days (3 and 4) stayed steady or slightly increased. Perhaps, this increase in responding derived from further acquisition of the heroin self-administration response, however, it is noted that following the first effective dose of LOB (1.0 mg/kg) a decrease in the average number of active lever presses on baseline days 5 and 6 were observed. If further acquisition were an issue, it would be predicted that selfadministration responding would increase further yet on days 5 and 6 unless conditioned aversive stimuli linked to higher lobeline doses transferred to baseline training sessions. Such conditioned aversion is not likely to have occurred, however, because baseline days 5 and 6 were not significantly different from baseline days prior to administration of lobeline (days 1 and 2). The more heuristic interpretation, then, would be one based on lobeline-induced antagonism of heroin reinforcement.
As discussed, LOB interrupts the activity of VMAT2, preventing vesicular DA transport within the pre-synaptic terminal (Felpin and Lebreton, 2004) and the attendant compromise in DA activity in the NAc may challenge the reward properties of heroin. This potential direct interference with the activation of the DA reward circuit may interfere with heroin drugseeking, and could account for the pattern of results observed in this study. Alternatively, the aforementioned antagonistic action of LOB on the μ-opiate receptor may have challenged disinhibition of GABA modulation of Glu stimulation of DA neurons projecting from the VTA to the NAc, ultimately preempting heroin-induced elevation of DA in this brain region and therein lessening the functional reward value of the drug. In either the direct or indirect case, LOB would attenuate i.v. heroin self-administration, as was observed here.
Whatever the mechanism(s), the results from the present study increase our understanding of potential chemical interventions and therein add opiates to the growing list of abused drugs for which LOB could potentially become part of an extensive pharmacotherapy regimen. The implications along these lines are profound. Currently, methadone is the treatment of choice for heroin addiction (Fugelstad, et al., 2007) , but it comes with established risks. Specifically, methadone overdose (death) is much more common than many people realize (Srivastava and Kahan, 2006; Zador, 2007) , and the development of potentially safer, substitute pharmacotherapies is desired. In this regard, the fact that LOB acts antagonistically on the opiate system may offer a reliable and possibly less dangerous way to manage some individual addiction profiles.
